CTOR

Citius Oncology, Inc.

Citius Oncology, Inc. (CTOR) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.

Quantitative Factor Evaluation • Updated

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 B- (3.0) A+ (5.0) C (2.4) C- (2.1) C+ (2.6) B- (3.0)
2026-11-04 B- (3.0) A+ (5.0) C (2.4) C- (2.1) C+ (2.7) B- (3.0)
2026-10-28 B- (3.0) C+ (2.5) C (2.5) B- (3.1) C+ (2.7) C+ (2.7)
2026-10-21 B- (3.0) C+ (2.5) C (2.4) B- (3.1) C+ (2.6) C+ (2.7)

Showing the last month only. Subscribe for the full factor score history.

For more — Subscribe